#USA #Miami #FDA Approval #Portal Access #Flexi-Port™

PorTal Access Secures FDA Clearance for FLEXI-PORT™ System

On June 22, 2026, PorTal Access, Inc. made headlines after achieving FDA clearance for its groundbreaking FLEXI-PORT™ system, designed specifically for vascular access. This announcement marks a significant milestone for the medical device company, which focuses on advancing vascular access technologies.

The FLEXI-PORT™ system is a customizable power injectable implantable port intended for long-term access in patients of all ages, from adults to pediatrics. This innovative solution is available in both 5Fr and 6Fr configurations, making it adaptable for implantation in various body areas, including the chest and the arm. With its versatile design, the FLEXI-PORT™ embraces a range of clinician preferences while also catering to diverse patient needs across multiple clinical environments.

Developed to overcome common difficulties associated with vascular access, FLEXI-PORT™ prioritizes procedural simplicity and patient-centered care. Notably, it is the only flexible port currently available in the market, requiring only a small incision for implantation. This feature streamlines procedures and enhances the overall experience for both patients and healthcare providers.

Dr. Michael Tal, the founder and CEO of PorTal Access, expressed his enthusiasm, calling the FDA clearance, "an incredibly meaningful moment for our company and the culmination of years of dedication and innovation." He elaborated on how the company's vision has always revolved around rethinking the chemotherapy port placement process to improve experiences for patients and caregivers alike. The FDA's approval represents a pivotal step toward bringing their transformative technology into clinical settings across the country.

Following this clearance, PorTal Access is poised to embark on commercialization efforts and clinician training programs. The company plans to collaborate with healthcare systems to increase the availability of the FLEXI-PORT™ system throughout the United States. Angela Dotson, the COO and Head of Business Development at PorTal, remarked that this marks a transition from building to scaling their operations. With the goal of expanding engagement with providers and health systems, PorTal aims to forge strong relationships with distributors and strategic partners as they introduce FLEXI-PORT™ to the market.

Innovative by design, the FLEXI-PORT™ is a game changer in the field of chemotherapy ports, representing the first substantial advancement in over three decades. Over 85% of the funds that supported its development were contributed by physicians actively engaged in placing chemo ports or managing patients. This remarkable backing highlights the confidence and support the medical community has for this new technology.

In closing, PorTal Access is setting its sights on a future where the FLEXI-PORT™ can play a crucial role in lifting the burden of traditional vascular access methods. With its commitment to elevating the patient experience while enhancing procedural efficiency for clinicians, the company is truly paving the way for next-generation vascular access solutions.

About PorTal Access

PorTal Access is dedicated to revolutionizing vascular access through innovative technologies. The company's mission centers around improving procedural efficiency, expanding access to care, and enhancing patient experience. Focused on developing next-generation solutions, PorTal aims to simplify procedures, improve outcomes, and broaden treatment options for patients worldwide.